Status:
UNKNOWN
Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Background: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the se...
Eligibility Criteria
Inclusion
- • Male or female ≥ 18 years
- Living donor
- Low immunological risk (defined as):
- First (primary) transplant
- ≤ 4 antigen mismatches (HLA matching scheme)
- Negative HLA Ab screening
Exclusion
- • High immunological risk
- HLA identical or zero mismatched transplants
- Receiving cyclosporin as primary maintenance immunosuppressant
- Human immunodeficiency virus (HIV) co-infection
- Pregnant or nursing female
- Has received an investigational medication within the past 30 days
- Has a known contraindication to the administration of Basiliximab
- Suspected or known to have a serious infection
- Multi-organ transplant
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04404127
Start Date
September 1 2020
End Date
May 1 2025
Last Update
February 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Faisal Specialist Hospital and Research Centre (KFSHRC)
Riyadh, Saudi Arabia, 11211